AI Imaging Biomarkers
for Precision Oncology

Picture Health unlocks the power of medical imaging with novel AI tools.
Our Px platform transforms radiology and pathology images into actionable insights by quantifying novel biological properties of tumors and their surroundings. 

Interpretable biomarkers built on these properties can better characterize patients and enhance patient selection, enabling biopharma and researchers to achieve better clinical trial results; and clinicians to optimize treatment strategies based on each patient's cancer tumor profile. 

Proven
Tech:

25

Patents

80+

Papers & Abstracts

Home-page-About-us-1024x594

Why Picture Health?

Tumor-white

Rooted in Biology

Px AI is interpretable because it directly examines biological tumor properties.
Screenshot 2025-01-03 at 11.19.37 AM - Edited (1)-1

Multimodal

We can integrate radiology, pathology, genomic, and clinical data for comprehensive characterization.
Radiology-Pathology

Requires only Routine Data

Px AI provides insights in minutes without additional tissue or lab tests.

What is Px?

Picture Health’s Px platform leverages a proprietary Feature Library to quantify tumor properties and build customizable biomarkers quickly, and without the need for large datasets.

 
These new insights allow for better and earlier response prediction as well as improved patient characterization and selection. By using routine clinical imaging and other data, Px eliminates the need for additional tissue or esoteric testing which allows the creation of AI biomarkers for all current and retrospective oncology trials. 


Px builds on a decade of scientific AI health imaging research. Taking advantage of the latest advancements in digitization and AI to analyze biologically relevant features that cannot be quantified manually to provide deeper characterization of the tumor and its surrounding environment. 

Pancreas-Thumbnail

News

  • NPJ Precision Oncology

    Collagen disorder architecture featuresare associated with clinical, molecular,genetic factors and survival outcomes inc....

    Published on: September 16, 2025

     NPJ Precision Oncology
  • OncLive

    Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

    Published on: July 8, 2025

     OncLive
  • npj - precision oncology

    Computationally integrating radiology and pathology image features for predicting treatment benefit and outcome in lung ....

    Published on: June 4, 2025

     npj - precision oncology
  • Picture Health Announces Strategic Partnership with Image Analysis Group to Advance AI-Driven Imaging Endpoints in Oncol....

    Published on: May 30, 2025

  • ASCO Annual Meeting

    Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HN....

    Published on: May 28, 2025

     ASCO Annual Meeting